Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck

Min Hee Hong, Chang Gon Kim, Yoon Woo Koh, Eun Chang Choi, Jinna Kim, Sun Och Yoon, Hye Ryun Kim, Byoung Chul Cho

Research output: Contribution to journalArticle

Abstract

Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m 2 ) on days 1 and 8 plus cisplatin (80 mg/m 2 ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.

Original languageEnglish
Pages (from-to)55-62
Number of pages8
JournalHead and Neck
Volume40
Issue number1
DOIs
Publication statusPublished - 2018 Jan

Fingerprint

Salivary Gland Neoplasms
Head and Neck Neoplasms
Cisplatin
Safety
Drug Therapy
Disease-Free Survival
Survival Rate
Survival
vinorelbine

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

@article{3a54408b4b2a406eb565cf75c0bf336f,
title = "Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck",
abstract = "Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m 2 ) on days 1 and 8 plus cisplatin (80 mg/m 2 ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0{\%}, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.",
author = "Hong, {Min Hee} and Kim, {Chang Gon} and Koh, {Yoon Woo} and Choi, {Eun Chang} and Jinna Kim and Yoon, {Sun Och} and Kim, {Hye Ryun} and Cho, {Byoung Chul}",
year = "2018",
month = "1",
doi = "10.1002/hed.24933",
language = "English",
volume = "40",
pages = "55--62",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. / Hong, Min Hee; Kim, Chang Gon; Koh, Yoon Woo; Choi, Eun Chang; Kim, Jinna; Yoon, Sun Och; Kim, Hye Ryun; Cho, Byoung Chul.

In: Head and Neck, Vol. 40, No. 1, 01.2018, p. 55-62.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck

AU - Hong, Min Hee

AU - Kim, Chang Gon

AU - Koh, Yoon Woo

AU - Choi, Eun Chang

AU - Kim, Jinna

AU - Yoon, Sun Och

AU - Kim, Hye Ryun

AU - Cho, Byoung Chul

PY - 2018/1

Y1 - 2018/1

N2 - Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m 2 ) on days 1 and 8 plus cisplatin (80 mg/m 2 ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.

AB - Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m 2 ) on days 1 and 8 plus cisplatin (80 mg/m 2 ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.

UR - http://www.scopus.com/inward/record.url?scp=85038233746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038233746&partnerID=8YFLogxK

U2 - 10.1002/hed.24933

DO - 10.1002/hed.24933

M3 - Article

C2 - 29044862

AN - SCOPUS:85038233746

VL - 40

SP - 55

EP - 62

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 1

ER -